NuCana Plc (NCNA)
1.37
-0.01
(-0.72%)
USD |
NASDAQ |
Sep 02, 16:00
1.43
+0.06
(+4.38%)
After-Hours: 20:00
NuCana Research and Development Expense (TTM) : 12.59M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.59M |
| March 31, 2026 | 19.05M |
| December 31, 2025 | 16.89M |
| September 30, 2025 | 15.52M |
| June 30, 2025 | 17.45M |
| March 31, 2025 | 16.50M |
| December 31, 2024 | 22.93M |
| September 30, 2024 | 30.51M |
| June 30, 2024 | 35.06M |
| March 31, 2024 | 31.48M |
| December 31, 2023 | 31.15M |
| September 30, 2023 | 38.11M |
| June 30, 2023 | 37.38M |
| March 31, 2023 | 40.46M |
| December 31, 2022 | 44.85M |
| September 30, 2022 | 43.72M |
| Date | Value |
|---|---|
| June 30, 2022 | 47.40M |
| March 31, 2022 | 51.28M |
| December 31, 2021 | 50.62M |
| September 30, 2021 | 46.82M |
| June 30, 2021 | 42.36M |
| March 31, 2021 | 37.72M |
| December 31, 2020 | 33.30M |
| September 30, 2020 | 29.43M |
| June 30, 2020 | 27.50M |
| March 31, 2020 | 27.10M |
| December 31, 2019 | 25.18M |
| September 30, 2019 | 24.50M |
| June 30, 2019 | 22.87M |
| March 31, 2019 | 23.00M |
| December 31, 2018 | 22.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biodexa Pharmaceuticals Plc | 5.234M |
| Mereo BioPharma Group Plc | 14.98M |
| BioNTech SE | 2.414B |
| Silence Therapeutics Plc | 43.54M |
| Autolus Therapeutics Plc | 112.42M |